NCT01204476 2016-07-15Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaNational Cancer Institute (NCI)Phase 1 Completed27 enrolled